Sheet	110	f 2								
Fasin	79	Q-144	19							
NPE 4						DOCKET NO. 204984		APPLN. 1	APPLN. NO. 10/081,705	
U.S. Department of Commerce						[formerly 22499-68466]				
- n 2006 w										
EB 0 2 1006 Date Filed: January 30, 2006						APPLICANT: John Barthelow CLASSEN				
ľ		S	7							
Wa-		MART				FILING DATE: 0	2/21/2002	GROUP 2	161	
U.S. PATENT						DOCUMENTS			····	
Examiner				Desc			GI	Subclass	Filing Date if	
Initia	4		Document Number	Date		Name	Class	Subclass	appropriate	
Elek	7		5,723,283	03/03/1998	C	LASSEN	435	4		
CHA	~	B	5,728,385	03/17/1998		LASSEN	424	201.1		
$\vdash \vdash$	-	C	6,219,674	04/17/2001		LASSEN	707	104		
├─┼	ᅱ	D	6,584,472	04/24/2003		LASSEN	707	104.1		
		E	90/007,638	07/22/2005		LASSEN				
 . /		F	90/007,639	07/22/2005	CLASSEN			 		
		<u> </u>				Including Author, Title, Date,		ges etc.)		
	7	1 1	Paker v. Seev of Den	CONTENT(S)	Human Sar	No 99-653V	2003 WI 2241	6622 (Ct Fed	Cl Sept 26	
Ele	[1	Baker v. Secy of Dept. of Health and Human Servs., No. 99-653V, 2003 WL 22416622, (Ct. Fed. Cl. Sept. 26, 2003)							
Zav	-	2	A. Bate, et al., "A Bayesian neural network method for adverse drug reaction signal generation," Eur J Clin							
1 [2			· · · · · · · · · · · · · · · · · · ·					
		3	Pharmacol 54(4) (June 1998) 315-321 C. Baum, et al., "The Spontaneous Reporting System in the United States," Pharmacoepidemiology, 2nd ed.							
		١								
		New York: John Wiley & Sons, 1994, 125-137 D. Bradbury, "A Bitter Pill to Swallow," Computing, 34-35, February 9, 1995								
	\dashv	5	D. Classen et al., "Adverse Drug Events in Hospitalized Patients," 277 JAMA, 301-306 (1997)							
 		6	D. Classen et al., "Computerized Surveillance of Adverse Drug Events in Hospital Patients," 266 JAMA 2847-2851							
	(1991)									
		7	D. Classen et al., "Description of a Computerized Adverse Drug Event Monitor Using a Hospital Information							
1 \		•	System," 27 Hosp. Pharm. 774, 776-779, 783 (1992)							
		8	D. Classen & S. Pestotnik, "The Computer-Based Patient Record," Hospital Epidemiology and Infection							
		•	Control. 141-154 (2nd Ed., New York: Lippincott Williams & Williams 1999)							
\Box		9	R. Evans et al., "A Computer-Assisted Management Program for Antibiotics and Other Antiinfective Agents," 338							
1 1	1		The New England Journal of Medicine, 232-238 (1998)							
		10	2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1							
			Computer Applications in Medical Care, 23-27 (1992)							
		11	R. Evans et al., "Evaluation of a Computer-Assisted Antibiotic-Dose Monitor," 33, Annals. Pharm., 1026-1031							
			(1999)							
	12 R. Evans et al., "Preventing Adverse Drug Events in Hospitalized Patients," 28 Ann. Pharm. 523-527 (1994)								-527 (1994)	
		13	R. Evans et al., "Prevention of Adverse Drug Events through Computerized Surveillance," 16th Annual Symposium							
			of Computer Applications in Medical Care, 437-441 (1993) R. Evans et al., "Using a Hospital Information System to Assess the Effects of Adverse Drug Events," Seventeenth							
1		14						verse Drug Eve	ents," Seventeenth	
			Annual Symposium on Computer Applications in Medical Care, 161-165 (1994)							
	15 G. Faich, US Adverse Drug Reaction Surveillance 1989-1994, Pharmacoepidemiology and Drug Safety 5:							rug Sajety 5:393-		
			398 (1996)							
	_	16	Federal Register, vol. 58, no. 105, docket no. 93N-0072 (June 3, 1993)							
		17	Finney, D. J. Systematic Signalling of Adverse Reactions to Drugs, Methods of Information in Medicine, 13							
\vdash			(1974) 1-10							
$\vdash \vdash$		18	International Reporting of Adverse Drug Reactions, Final Report of CIOMS Working Group, 1990 Jim Kling, "From hypertension to angina to Viagra," Modern Drug Discovery 1(2) (1998), available at							
		19	Jim Kling, "From hy	pertension to ang	gina to Viag	ga, <i>Modern Dru</i> ahtm	g Discovery 1(2,	, (1770), avalla	וטוב עו	
├ ──┼		30	http://pubs.acs.org/ho	From Association	n to Alas	A Davicad Anner	ach to Internation	nal Signal Ana	lycie "	
	,	20	M. Lindquist et al., "From Association to Alert-A Revised Approach to International Signal Analysis,"							
 	Pharmacoepidemiology and Drug Safety 8:S15-S25 (April 1999) 21 David J. Morrow, "New Profits in Old Bottles," N.Y. Times, March 19, 1999									
Fvo	21' David J. Morrow, "New Profits in Old Bottles," N.Y. Times, March 19, 1999 Examiner Signature: Date Considered: / /								1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if nov in conformance and not considered. Include copy of this form with next communication to applicant(s).

PTO-1449.doc

				مستوع والمناز						
Sheet 2										
Form P	ΓΟ-14	U.S. Department of Commerce	DOCKET NO. 204984 [formerly 22499-68466]	APPLN. NO. 10/081,705						
		Date Filed: January 30, 2006	APPLICANT: John Barthelow CLASSEN							
			FILING DATE: 02/21/2002	GROUP 2161						
		OTHER DOCUMENT(S) (Including								
Elek	22	C.A. Naranjo et al., "A method for estimating the (2):239-45 (1981)								
	23	V. Pinkston & E. J. Swain, "Management of Adv Storage and Retrieval," Detection of New Advers Macmillan Reference Ltd.)								
	24	ne Adverse Event Reporting								
	25	System (VAERS)," MEDWATCH Continuing E Statement of Susan S. Ellenberg before the U.S. www.fda.gov/ola/1999/anthrax.html (July 21, 19	House of Representatives, available of 999)							
	26	g Groups: Focus on Improving al Section, American 199) (Szarfman/abstract)								
	27	A. Szarfman, "New Methods for Signal Detect Boston, Mass., August 28, 1999 (Szarfman/pp	tion," 15th International Conference of	on Pharmacoepidemiology,						
1//										
\ \\/	29	http://www.fda.gov/medwatch/report/DESK/adv Vaccine Safety Forum, Summaries of Two Work		cademy Press 1997)						
<u> </u>										
	 									
ļ	 									
ļ	 									
ļ	 									
	+			/						
	+									
	+	<u> </u>		**************************************						
	+-									
<u> </u>	 									
	1									
				······································						
										
ļ										
	 '									
l	<u> </u>									
 	 '	ļ								
<u> </u>	 									
ļ	 									
	 									
 	 '									
 	 '									
Examin	er Sig	inature: Goldward	Date Considere	ed: 3/15/06						
4										

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

PTO-1449.doc00